{"name":"LYSOGENE","slug":"lysogene","ticker":"","exchange":"","domain":"","description":"Lysogene is a clinical-stage biotechnology company focused on the development of gene therapies for central nervous system (CNS) diseases. The company's lead candidate, LYS-SAF302, is in Phase 2 clinical trials for the treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA).","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNMVZ2ME05a0xBcVhFeW50STZYSTRXUk1vaUhIWFRrOUc1bEdFUDBzTExuZkxTc21ZSmdIazhHT0pYNkVaZEFucHQ1MTcxN09JVnFQd3ZRaHgzMW5KeXhnMFA4ZEVhOXJSeW5PT0ZBU25yQVN3d1ZTQnZhMTFwcmMtOVliMjJHTGhlTmZsclQwMlJJQjQ5aTN5ZC1vTGZEWGItTjhKbUxzUHg4MUF5T2JKeDBNcHBBcmZn?oc=5","date":"2022-12-07","type":"trial","source":"Fierce Biotech","summary":"Lysogene, looking for saving grace after trial flop, suspends stock trading and seeks partners - Fierce Biotech","headline":"Lysogene, looking for saving grace after trial flop, suspends stock trading and seeks partners","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOMzdZUUNSU2hveDJORVFZOHZBSjhlN3I4dWxOQ1hRaF9YTU82WjNJdTJhRzBtS29yUlE4WHVLUC1hYTExODlQRW0wMFJrM0hXdFZBb2NzZmhkUEhrNUxKcjBjTXVZaDZFbmF0UDZpLXMwWmN1NHZMc09OUlZiQ0hQTFpITmNiNW5zYUF2R1pqZXFFeEkxY2pnOEVLX2xjMVdDQ2VYMFNTTmVZSmVwaVN6UnRiUkNnMjVxbElEcEtRbWVHdw?oc=5","date":"2022-11-18","type":"trial","source":"Fierce Biotech","summary":"Lysogene's lead gene therapy flunks phase 2/3 trial almost a year after Sarepta walked out - Fierce Biotech","headline":"Lysogene's lead gene therapy flunks phase 2/3 trial almost a year after Sarepta walked out","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQMm9hRGxpa1pZVFhxNHdSX0hfc3B3Z0dGQ3dpQ085Q3o2TnUycjBENFBrXzdsN0o5clJ6U1lxMENnVXNIbmh6NVdMcUswbzN1Tnd1YVFjN0Z2TDBrTDFSUkxLSTNRQk9zZzh2bkFfNHJ1blFPNFhsMVdMelJnc0NIT1FZNHJYRU52M2FVa3NMSjhyTTJLNXVn?oc=5","date":"2022-01-13","type":"trial","source":"Fierce Biotech","summary":"Sarepta, with pivotal data in sight, dumps Lysogene gene therapy - Fierce Biotech","headline":"Sarepta, with pivotal data in sight, dumps Lysogene gene therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPSlRCT0xtRDRYVEM0ODFZNXBaZlljalRvNHpUaVoxdmVxOU4xdDdCNEFFMDE0YmUtdXV1bm1wUGw4amtBTHNLSEpRZ2puQkVjaUNFMmxrOTA3ZWhlWVZiV2hHNHAyQjEyaElPT0JhZEpXSlltdzhIc1JTSVFCQkVTdi1teHJSRkRxZW8zdzhJaDlwcGhkSzhLSnlQdw?oc=5","date":"2020-05-27","type":"deal","source":"Contract Pharma","summary":"Novasep, Lysogene Enter Gene Therapy Collaboration - Contract Pharma","headline":"Novasep, Lysogene Enter Gene Therapy Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOYjVjVDZWS3Z6dGozcXdVOEx0ZXhHWENkZEE5aE03RF9lZUZ0bnZQcFlfOXhTV3pIX283SWxfbFhKUXRkZDJmTGxKdENNdy1ieG5nN2ZSSEVwa2FCY1M5eGZkelF3bWF1eHRhaGFrNG9xYTNwcjQ3T251RXMxem1iTHoyX1lEdGFlSzhFR0JfSFViR1NQdjg1VXBFTGlpSUx4VWg4NUczcDF4UnBLZDVXOXJKQ09sZld4Y0xXS2FHeWM?oc=5","date":"2015-12-25","type":"earnings","source":"The New York Times","summary":"Parents of Children With Rare Diseases Find Hope in For-Profit Companies (Published 2015) - The New York Times","headline":"Parents of Children With Rare Diseases Find Hope in For-Profit Companies (Published 2015)","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}